PubMed Health⌕ Search

Biomedical subjects

M Orizaga

Publications and source records attributed to M Orizaga.

17 recordsLinked to original sources
PubMed1990

Morphea coexisting with lichen sclerosus et atrophicus.

A 65-year-old woman presented with four autoimmune diseases. These include morphea, lichen sclerosus et atrophicus, insulin-dependent diabetes mellitus, and autoimmune thyroid disease. The relationship between morphea and lichen sclerosus et A is discussed, as is the link between these conditions and autoimmunity.

Aged↗
PubMed1990

Computed tomography fluid-fluid level in bone metastasis.

Fluid-fluid levels have been reported in a variety of primary bone and soft-tissue tumours, most frequently in aneurysmal bone cysts, but have never been reported in a metastatic bone lesion. To emphasize such a possibility the authors present a case in which serial computed tomography demonstrated a pulmonary nodule, paratracheal adenopathy and a fluid-fluid level within a rib lesion. Further investigation confirmed a rib metastasis from primary carcinoma of the bronchus.

Bone Neoplasms↗
PubMed1980

Ulcerative enterocolitis in dogs induced by drugs.

An ulcerative enterocolitis was induced in dogs by two drugs; cinchophen given intravenously or indomethacin given orally. Ulcers were closely associated with Peyer's patches with either drug. Granulomata were occasionally seen in the mucosa and adjacent mesenteric nodes of dogs who received cinchophen. Transmural inflammation was seen only in some dogs who received indomethacin. A skip-like distribution of mucosal lesions was seen, induced by either drug and corresponding to the skip-like collections of lymphoid follicles. An explanation of the pathogenesis of these lesions is offered in the light of recent advances in the understanding of the immune response of gut-associated lymphoid tissue.

Animals↗
PubMed1976

Immunochemotherapy of lung cancer.

After surgical resection of their primary lung cancer, 33 patients were randomized into one of three groups. The first received high-dose methotrexate once per month with citrovorum rescue, for 3 months. The second group were immunized monthly with a homogenate of Freund's complete adjuvant and carefully characterized soluble antigen derived from allogeneic lung cancer cells of appropriate histology, for 3 months. The third group received a combination of methotrexate and immunization monthly, for 3 months. Each patient was monitored immunologically before, during, and after the treatment period, by use of delayed hypersensitivity reactions to recall and cancer antigens, in vitro lymphocyte response to mitogens, and mixed lymphocyte blocking factor activity. The group that received methotrexate showed little change in skin reactivity, a reduction of blocking factor activity, and significant rebound overshoot in in vitro lymphocyte performance. The immunized group showed a tendency to production of blocking factor activity, striking conversion and enhancement of skin reactivity, and little change in in vitro lymphocyte performance. The immunochemotherapy group showed dramatic increases in specific skin reactivity to cancer antigens, up to 2 years after treatment, in vitro lymphocyte rebound overshoot, and reduction of blocking factor activity production. Classic life table analysis of the probability of freedom from metastases in patients with stage-I cancer indicate that the disease-free interval in patients who received methotrexate is longer than in historic and concomitant controls but not as long as in those who received immunization. The best group appear to be those who received combination immunochemotherapy. We emphasize that the small numbers in this pilot study do not yet allow firm conclusions to be made.

Adult↗